Christopher Beynon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Christopher Beynon has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
Andreas W. Unterberg
Department of Neurosurgery, Heidelberg University Hospital, Heidelberg, Germany
20 shared publicationsOliver W. Sakowitz
Department of Neurosurgery, Heidelberg University Hospital, Heidelberg, Germany; Department of Neurosurgery, Ludwigsburg Hospital, Ludwigsburg, Germany
12 shared publications- Andreas Unterberg
Department of Neurosurgery, University Hospital Heidelberg, 69120 Heidelberg, Germany
8 shared publications Anna Potzy
Department of Neurosurgery, Heidelberg University Hospital, Heidelberg, Germany
5 shared publications- Alexander Younsi
Medical Faculty, Heidelberg University, 69120 Heidelberg, Germany
4 shared publications C. J. Reuß
Klinik für Anästhesiologie und operative Intensivmedizin, Klinikum Stuttgart, Stuttgart, Deutschland
4 shared publications
Latest Publications
- 1 January 2026
- Published by Georg Thieme Verlag KG
Erkrankungen des Nervensystems
- Open Access
- 6 January 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 7 (1)
Combination tumors of the nervous system: A single-center analysis of a rare condition and comprehensive review of the literature
Background: With less than 650 published cases, combination tumors of the nervous system, that is, two locally intertwined but histologically distinct tumor entities, pose a rare constellation, its clinical relevance still being a matter of debate. Methods: A consecutive cohort of 2530 patients operated on meningioma or hemangioblastoma between 2009 and 2021 was retrospectively screened for concomitant neoplastic disease to identify cases of combination tumors. Additionally, all available literature published between 1930 and 2021 was compiled in a comprehensive review. Results: Our cohort comprised 144 cases of patients with concomitant neoplastic disease and among those 10 instances of combination tumors. Another instance occurred after our screening period. Benign entities were meningiomas, but no hemangioblastoma. Contributing tumors were adenocarcinomas, lymphoma, glioblastoma, pituitary neuroendocrine tumors, and neurinoma. Patients’ age ranged from 41 to 81 years with a slight preference for females. Identification of concomitant neoplasia was first achieved due to the combination tumor in about half of our cases. For the rest, median latency until manifestation of the combination tumor was 9 years. The odds ratio for a combination tumor was 17.6 for meningioma patients with known concomitant neoplasia, but it was preoperatively suspected in 18.2% of cases only. Conclusion: Presenting one of the largest clinical series, we provide evidence that known concomitant neoplasia in patients with suspected meningioma should make clinicians consider a combination tumor. Confirmation may lead to therapeutic consequences, largely contributing to long-term prognosis. Furthermore, we present the most extensive literature review on the matter to date.
- 6 January 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 7 (1)
Open AccessCombination tumors of the nervous system: A single-center analysis of a rare condition and comprehensive review of the literature
Background: With less than 650 published cases, combination tumors of the nervous system, that is, two locally intertwined but histologically distinct tumor entities, pose a rare constellation, its clinical relevance still being a matter of debate. Methods: A consecutive cohort of 2530 patients operated on meningioma or hemangioblastoma between 2009 and 2021 was retrospectively screened for concomitant neoplastic disease to identify cases of combination tumors. Additionally, all available literature published between 1930 and 2021 was compiled in a comprehensive review. Results: Our cohort comprised 144 cases of patients with concomitant neoplastic disease and among those 10 instances of combination tumors. Another instance occurred after our screening period. Benign entities were meningiomas, but no hemangioblastoma. Contributing tumors were adenocarcinomas, lymphoma, glioblastoma, pituitary neuroendocrine tumors, and neurinoma. Patients’ age ranged from 41 to 81 years with a slight preference for females. Identification of concomitant neoplasia was first achieved due to the combination tumor in about half of our cases. For the rest, median latency until manifestation of the combination tumor was 9 years. The odds ratio for a combination tumor was 17.6 for meningioma patients with known concomitant neoplasia, but it was preoperatively suspected in 18.2% of cases only. Conclusion: Presenting one of the largest clinical series, we provide evidence that known concomitant neoplasia in patients with suspected meningioma should make clinicians consider a combination tumor. Confirmation may lead to therapeutic consequences, largely contributing to long-term prognosis. Furthermore, we present the most extensive literature review on the matter to date.
- 17 May 2023
- Published by Springer Nature in Die Anaesthesiologie
- Vol. 72 (7) , 518-525
Fokus Neurochirurgische Intensivmedizin 2021/2022
- 17 May 2023
- Published by Springer Nature in Die Anaesthesiologie
- Vol. 72 (7) , 518-525
Fokus Neurochirurgische Intensivmedizin 2021/2022
- 9 December 2021
- Published by Taylor & Francis in British Journal Of Neurosurgery
- Vol. 37 (1) , 108-111
Impact of ABO-blood group type on haemorrhagic and thromboembolic complications after resection of intracranial meningiomas
Recent studies have suggested an impact of the ABO-blood group type on thromboembolic and haemorrhagic events following trauma and surgical procedures. However, only limited data are available on the impact of ABO-blood group types in neurosurgical patients. The goal of the present study was to evaluate the role of the ABO-blood group type on the frequency of thromboembolic and haemorrhagic complications in patients treated surgically for intracranial meningiomas at our institution. We retrospectively analysed the medical records of consecutive patients undergoing resection of intracranial meningiomas at our institution during a period of 12.5 years (2006–2018). Clinical characteristics, modalities of surgical treatment, histopathological results and the postoperative course of patients were analysed with specific focus on ABO-blood group typing results, need for transfusion of blood products, events of postoperative thromboembolism and intracranial re-haemorrhage requiring surgical revision, as well as in-hospital mortality. A total of 1,782 patients were included in this study. Based on the ABO-blood group type, patients were subdivided into four categories, corresponding to their ABO-blood group: Blood group A (n = 773; 43%); blood group B (n = 222; 12%); blood group AB (n = 88; 5%); and blood group O (n = 699; 39%). Intracranial re-haemorrhage requiring re-craniotomy and haematoma evacuation occurred in a total of 49 patients (2.7%). Thromboembolic events such as pulmonary embolism occurred in a total of 27 patients (1.5%). Statistical analysis showed no significant differences regarding the ABO-blood group type in patients suffering from re-haemorrhage or thromboembolism compared with patients with uneventful course after surgery. The overall in-hospital mortality rate was 0.17% (n = 3). Our findings suggest a lack of relevance of the ABO-blood group type regarding haemorrhagic and thromboembolic complications in patients undergoing neurosurgical meningioma resection.
- 9 December 2021
- Published by Taylor & Francis in British Journal Of Neurosurgery
- Vol. 37 (1) , 108-111
Impact of ABO-blood group type on haemorrhagic and thromboembolic complications after resection of intracranial meningiomas
Recent studies have suggested an impact of the ABO-blood group type on thromboembolic and haemorrhagic events following trauma and surgical procedures. However, only limited data are available on the impact of ABO-blood group types in neurosurgical patients. The goal of the present study was to evaluate the role of the ABO-blood group type on the frequency of thromboembolic and haemorrhagic complications in patients treated surgically for intracranial meningiomas at our institution. We retrospectively analysed the medical records of consecutive patients undergoing resection of intracranial meningiomas at our institution during a period of 12.5 years (2006–2018). Clinical characteristics, modalities of surgical treatment, histopathological results and the postoperative course of patients were analysed with specific focus on ABO-blood group typing results, need for transfusion of blood products, events of postoperative thromboembolism and intracranial re-haemorrhage requiring surgical revision, as well as in-hospital mortality. A total of 1,782 patients were included in this study. Based on the ABO-blood group type, patients were subdivided into four categories, corresponding to their ABO-blood group: Blood group A (n = 773; 43%); blood group B (n = 222; 12%); blood group AB (n = 88; 5%); and blood group O (n = 699; 39%). Intracranial re-haemorrhage requiring re-craniotomy and haematoma evacuation occurred in a total of 49 patients (2.7%). Thromboembolic events such as pulmonary embolism occurred in a total of 27 patients (1.5%). Statistical analysis showed no significant differences regarding the ABO-blood group type in patients suffering from re-haemorrhage or thromboembolism compared with patients with uneventful course after surgery. The overall in-hospital mortality rate was 0.17% (n = 3). Our findings suggest a lack of relevance of the ABO-blood group type regarding haemorrhagic and thromboembolic complications in patients undergoing neurosurgical meningioma resection.
- 10 August 2021
- Published by Springer Nature in Der Anaesthesist
- Vol. 70 (9) , 789-794
Neurochirurgische Intensivmedizin
- 10 August 2021
- Published by Springer Nature in Der Anaesthesist
- Vol. 70 (9) , 789-794
Neurochirurgische Intensivmedizin
- Open Access
- 20 July 2021
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 12
Long-Term Results of Neurological Outcome, Quality of Life, and Cosmetic Outcome After Cranioplastic Surgery: A Single Center Study of 202 Patients
Objective: An increased interest in the surgical procedures of decompressive craniectomy (DC) and subsequent cranioplasty (CP) has emerged during the last decades with specific focus on mortality and complication rates. The aim of the present study was to evaluate long-term neurological and cosmetic outcomes as well as Quality of Life (QoL) after CP surgery.Methods: We retrospectively reviewed the medical records of CP patients treated at our institution between 2004 and 2014 and performed a follow-up examination, with evaluation of neurological outcome using the modified Rankin Scale (mRS) and the Glasgow outcome scale (GOS), QoL (SF-36 and EQ-5D-3L). Furthermore, the cosmetic results after CP were analyzed.Results: A total of 202 CP-patients were included in the present study. The main indications for DC and subsequent CP were space-occupying cerebral ischemia (32%), traumatic brain injury (TBI, 26%), intracerebral or subarachnoid hemorrhage (32%) and infection (10%). During a mean follow-up period of 91.9 months 46/42.6% of patients had a favorable neurological outcome (mRS ≤ 3/GOS ≥ 4). Patients with ischemia had a significant worse outcome (mRS 4.3 ± 1.5) compared with patients after TBI (3.1 ± 2.3) and infectious diseases requiring CP (2.4 ± 2.3). The QoL analysis showed that Conclusion: Long-term outcome and QoL after CP were significantly influenced by the medical condition requiring DC. Early detection and evaluation of QoL after CP may improve the patient's outcome due to an immediate initiation of targeted therapies (e.g., occupational- or physiotherapy).
- 20 July 2021
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 12
Open AccessLong-Term Results of Neurological Outcome, Quality of Life, and Cosmetic Outcome After Cranioplastic Surgery: A Single Center Study of 202 Patients
Objective: An increased interest in the surgical procedures of decompressive craniectomy (DC) and subsequent cranioplasty (CP) has emerged during the last decades with specific focus on mortality and complication rates. The aim of the present study was to evaluate long-term neurological and cosmetic outcomes as well as Quality of Life (QoL) after CP surgery.Methods: We retrospectively reviewed the medical records of CP patients treated at our institution between 2004 and 2014 and performed a follow-up examination, with evaluation of neurological outcome using the modified Rankin Scale (mRS) and the Glasgow outcome scale (GOS), QoL (SF-36 and EQ-5D-3L). Furthermore, the cosmetic results after CP were analyzed.Results: A total of 202 CP-patients were included in the present study. The main indications for DC and subsequent CP were space-occupying cerebral ischemia (32%), traumatic brain injury (TBI, 26%), intracerebral or subarachnoid hemorrhage (32%) and infection (10%). During a mean follow-up period of 91.9 months 46/42.6% of patients had a favorable neurological outcome (mRS ≤ 3/GOS ≥ 4). Patients with ischemia had a significant worse outcome (mRS 4.3 ± 1.5) compared with patients after TBI (3.1 ± 2.3) and infectious diseases requiring CP (2.4 ± 2.3). The QoL analysis showed that Conclusion: Long-term outcome and QoL after CP were significantly influenced by the medical condition requiring DC. Early detection and evaluation of QoL after CP may improve the patient's outcome due to an immediate initiation of targeted therapies (e.g., occupational- or physiotherapy).
- 1 September 2020
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 79, 197-202
Prothrombin complex concentrate for vitamin K antagonist reversal in traumatic intracranial hemorrhage
- 1 September 2020
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 79, 197-202
Prothrombin complex concentrate for vitamin K antagonist reversal in traumatic intracranial hemorrhage
- Open Access
- 1 May 2020
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 87 (2) , E229
Letter: The Use of Absorbable Sutures in Neurosurgical Procedures in the Time of COVID-19
- 1 May 2020
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 87 (2) , E229
Open AccessLetter: The Use of Absorbable Sutures in Neurosurgical Procedures in the Time of COVID-19
- 1 December 2019
- Published by Elsevier in World Neurosurgery
- Vol. 132, 447-448
In Reply to the Letter to the Editor Regarding “Management of Spinal Emergencies in Patients on Direct Oral Anticoagulants”
- 1 December 2019
- Published by Elsevier in World Neurosurgery
- Vol. 132, 447-448
In Reply to the Letter to the Editor Regarding “Management of Spinal Emergencies in Patients on Direct Oral Anticoagulants”
- 1 November 2019
- Published by Elsevier in World Neurosurgery
- Vol. 131, e570-e578
Management of Spinal Emergencies in Patients on Direct Oral Anticoagulants
- 1 November 2019
- Published by Elsevier in World Neurosurgery
- Vol. 131, e570-e578
Management of Spinal Emergencies in Patients on Direct Oral Anticoagulants